Pleural Effusion
Welcome,         Profile    Billing    Logout  
 22 Companies   31 Products   31 Products   47 Mechanisms of Action   1 Trial   161 News 


123»
  • ||||||||||  ganitumab (AMG 479) / Takeda, ImmunityBio
    Phase classification, Trial termination, Combination therapy:  QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) -  Aug 23, 2024   
    P1/2,  N=213, Terminated, 
    Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; Subjects discontinued study
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Trial completion date, Trial primary completion date:  Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer (clinicaltrials.gov) -  Apr 19, 2019   
    P2,  N=22, Completed, 
    Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; Subjects discontinued study Enrolling by invitation --> Completed | Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019
  • ||||||||||  carboplatin / Generic mfg., paclitaxel / Generic mfg., irinotecan / Generic mfg.
    Enrollment change, Trial termination, Metastases:  Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer (clinicaltrials.gov) -  Feb 11, 2019   
    P2,  N=7, Terminated, 
    Enrolling by invitation --> Completed | Trial completion date: Dec 2018 --> Mar 2019 | Trial primary completion date: Mar 2018 --> Mar 2019 N=48 --> 7 | Active, not recruiting --> Terminated; Low accrual
  • ||||||||||  naproxen / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  The Effect of Non-Steroidal Anti-Inflammatory Drug Naproxen on Pleural Effusion Formation After Lung Resection (clinicaltrials.gov) -  Feb 15, 2018   
    P2,  N=7, Terminated, 
    Recruiting --> Completed | Trial completion date: Dec 2017 --> Mar 2018 N=300 --> 7 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2018 | Trial completion date: Dec 2016 --> Jan 2018; Recruitment futile
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  Using Ultrasound to Predict the Results of Draining Pleural Effusions (clinicaltrials.gov) -  Jan 10, 2018   
    P=N/A,  N=2, Terminated, 
    N=300 --> 7 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2018 | Trial completion date: Dec 2016 --> Jan 2018; Recruitment futile N=50 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2014 --> May 2017; Difficult to recruit to due to conflicting trials recruiting similar participants.
  • ||||||||||  Trial primary completion date:  Pigtail Catheter: a Less Invasive Option for Pleural Drainage of Recurrent Hepatic Hydrothorax (clinicaltrials.gov) -  Dec 27, 2017   
    P=N/A,  N=30, Recruiting, 
    N=50 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2014 --> May 2017; Difficult to recruit to due to conflicting trials recruiting similar participants. Trial primary completion date: Dec 2017 --> Dec 2022
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date:  Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer (clinicaltrials.gov) -  Dec 14, 2017   
    P2,  N=30, Enrolling by invitation, 
    Trial primary completion date: Dec 2017 --> Dec 2022 Trial primary completion date: Jun 2017 --> Mar 2018
  • ||||||||||  Trial completion, Head-to-Head:  DARTT: Drainage Amount for Removal of Thoracostomy Tube (clinicaltrials.gov) -  Jun 21, 2017   
    P=N/A,  N=280, Completed, 
    Trial primary completion date: Aug 2017 --> Dec 2017 Active, not recruiting --> Completed
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment change, Trial termination, Trial primary completion date:  BEVAP: Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer (clinicaltrials.gov) -  May 10, 2017   
    P1,  N=1, Terminated, 
    Active, not recruiting --> Completed N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Apr 2017; Insufficient Recruitment
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  Tubeless Versus Standard Upper Pole Percutaneous Nephrolithotomy (clinicaltrials.gov) -  Apr 12, 2017   
    P=N/A,  N=65, Terminated, 
    N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Apr 2017; Insufficient Recruitment N=140 --> 65 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2017
  • ||||||||||  Trial completion:  Electrical Impedance Imaging of Patients on Mechanical Ventilation (clinicaltrials.gov) -  Feb 1, 2017   
    P=N/A,  N=2, Completed, 
    N=140 --> 65 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Apr 2017 Recruiting --> Completed
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment status, Trial primary completion date:  Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer (clinicaltrials.gov) -  Oct 4, 2016   
    P2,  N=30, Enrolling by invitation, 
    Trial primary completion date: Sep 2016 --> Dec 2017 Recruiting --> Enrolling by invitation | Trial primary completion date: Jun 2016 --> Jun 2017
  • ||||||||||  Trial primary completion date:  Electrical Impedance Imaging of Patients on Mechanical Ventilation (clinicaltrials.gov) -  Jul 28, 2016   
    P=N/A,  N=4, Recruiting, 
    Recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Dec 2016 Trial primary completion date: Oct 2015 --> Oct 2016
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Talc in Treating Patients With Malignant Pleural Effusion (clinicaltrials.gov) -  Jun 26, 2016   
    P3,  N=501, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Trial primary completion date, HEOR:  Pleural Catheters Versus Thoracoscopic Pleurodesis (clinicaltrials.gov) -  Apr 11, 2016   
    P=N/A,  N=445, Completed, 
    Trial primary completion date: Mar 2016 --> Sep 2016 Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Apr 2016
  • ||||||||||  Trial primary completion date:  Tubeless Versus Standard Upper Pole Percutaneous Nephrolithotomy (clinicaltrials.gov) -  Apr 7, 2016   
    P=N/A,  N=140, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Apr 2016 Trial primary completion date: Dec 2015 --> Dec 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date, Surgery:  Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography (clinicaltrials.gov) -  Mar 24, 2016   
    P=N/A,  N=130, Completed, 
    Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Completed | N=80 --> 130 | Trial primary completion date: May 2017 --> Mar 2016
  • ||||||||||  Caprelsa (vandetanib) / Sanofi
    Trial termination, Pleural effusion:  Malignant Pleural Effusion With ZD6474 (clinicaltrials.gov) -  Mar 9, 2016   
    P2,  N=28, Terminated, 
    Recruiting --> Completed | N=80 --> 130 | Trial primary completion date: May 2017 --> Mar 2016 Completed --> Terminated; Slow Accrual
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) -  Feb 10, 2016   
    P1,  N=23, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=60 --> 23 | Trial primary completion date: May 2017 --> Jan 2016
  • ||||||||||  pemetrexed / Generic mfg.
    Trial completion, Trial primary completion date:  Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer (clinicaltrials.gov) -  Dec 12, 2015   
    P2,  N=64, Completed, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2015 --> Aug 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Dec 2015
  • ||||||||||  Trial completion, Surgery:  Pleural and Pericardial Effusion Following Open Heart Surgery (clinicaltrials.gov) -  Nov 17, 2015   
    P=N/A,  N=76, Completed, 
    Recruiting --> Completed | N=240 --> 120 | Trial primary completion date: Jun 2012 --> Jun 2013 Recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Surgery:  Fortified Skimmed Mother's Milk in the Management of Chylothorax (clinicaltrials.gov) -  Oct 14, 2015   
    P=N/A,  N=17, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=50 --> 17
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  TIME-1: The First Therapeutic Intervention in Malignant Pleural Effusion Trial (clinicaltrials.gov) -  Jul 20, 2015   
    P=N/A,  N=4, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | N=20 --> 4 | Trial primary completion date: Dec 2010 --> Dec 2014
  • ||||||||||  Trial primary completion date, HEOR:  Pleural Catheters Versus Thoracoscopic Pleurodesis (clinicaltrials.gov) -  Jul 17, 2015   
    P=N/A,  N=445, Active, not recruiting, 
    Recruiting --> Completed | N=20 --> 4 | Trial primary completion date: Dec 2010 --> Dec 2014 Trial primary completion date: Apr 2016 --> Apr 2017